Arcturus Therapeutics (ARCT) Tops Q1 EPS by $1.81

Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of $1.87, $1.81 better than the analyst estimate of $0.06. Revenue for the quarter came in at $80.3 million versus the consensus estimate of $37.94 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Bill.com (BILL) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 Guidance
• Ocean Power Technologies revises fiscal 2026 results after audit